Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models. - Wikidata - wikimedia - TriplyDB

Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.

Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.

http://www.wikidata.org/entity/Q33728180

about

The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.

P2860

Q51746838-F9BA3870-7483-4D8D-B09E-F5A9F8AAE351

P2860

Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.

http://www.wikidata.org/entity/Q33728180

description

2017 nî lūn-bûn

@nan

2017 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մարտին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Enhancement of radiosensitivit ...... eclinical glioblastoma models.

@ast

Enhancement of radiosensitivit ...... eclinical glioblastoma models.

@en

type

label

Enhancement of radiosensitivit ...... eclinical glioblastoma models.

@ast

Enhancement of radiosensitivit ...... eclinical glioblastoma models.

@en

prefLabel

Enhancement of radiosensitivit ...... eclinical glioblastoma models.

@ast

Enhancement of radiosensitivit ...... eclinical glioblastoma models.

@en

P1433

Q33728180-302BDE1B-F43D-4A77-8270-AF8143CEBCDF

P1476

Q33728180-61302DFA-2893-4D72-9C27-5734329348DA

P2093

Q33728180-3185280B-F494-423A-9672-1AABCEA7DD37

Q33728180-7B45E3E6-8D91-45A0-9C8E-D87FA46E7BBB

Q33728180-80612465-B079-422D-8316-33A612FED833

Q33728180-91901AAF-FA64-4F72-8708-009DC0557667

Q33728180-9E510793-36E4-40AD-B342-7DDB6C670718

Q33728180-A44D99C7-86B9-4AF3-8352-66C07DE86371

Q33728180-B53A988B-CDA0-43F9-A185-E134313BAFDC

Q33728180-BA2F806B-A5C6-4895-8786-3BBE13717B1C

Q33728180-C5DD7BE7-CD4C-4309-ACCB-AA1030F152FD

Q33728180-D79CAC46-35ED-427F-84DC-6B29B440EEBC

P2860

Q33728180-02789C68-1606-43AF-930C-FD887881AAFE

Q33728180-0579A866-BE68-4088-B6A2-C34A2847E18D

Q33728180-068CC629-807A-4C53-A71A-E66606516C5F

Q33728180-07646AA1-DF9D-4486-9860-6DF9A24EC6AD

Q33728180-0A61C856-C516-436C-B383-71FF90E93B7C

Q33728180-0B12CD6C-00B8-48C0-9522-AC7FA49F32C5

Q33728180-0B862D1B-0163-4734-BAE7-263DED32D7AB

Q33728180-1D6D59F9-DA41-497B-908B-CBBA1B8AE155

Q33728180-203C31F3-B873-4F17-B59E-0C045F1AED90

Q33728180-244FDCB1-9FD0-4D32-87B9-9A9EEAF79B94

P304

Q33728180-702F882F-C636-48FE-815F-7B89515889F1

P31

Q33728180-50ED5B8C-F769-4D90-AF02-CE9CD72DF29A

P356

Q33728180-89B72D62-9E4F-4F46-9122-A11D3EB1D8E3

P407

Q33728180-90682C7C-2B10-4446-8C60-E379A3CE32CB

P433

Q33728180-02B03289-00F0-4770-8125-C59C9241136A

P478

Q33728180-6640C13A-87C8-4FC2-A3B1-A4E091DC437D

P50

Q33728180-7BD6129A-93A8-477C-8335-4E57A9D2AA56

P577

Q33728180-4E2F10D5-5712-4395-9C5A-8F8BB910EFCA

P698

Q33728180-9A69C98F-1827-4079-858F-002FB86115FF

P921

Q33728180-DF04B4DA-6240-41F2-9835-8D530E29F0FB

P932

Q33728180-262CFD99-0446-4F51-9CDF-6B0F333EA853

P356

ONCOTARGET.16168

P1433

P1476

Enhancement of radiosensitivit ...... reclinical glioblastoma models

@en

P2093

Alessandro Colapietro

http://www.w3.org/2001/XMLSchema#string

Antonella Vetuschi

http://www.w3.org/2001/XMLSchema#string

Claudia Mattei

http://www.w3.org/2001/XMLSchema#string

Claudio Festuccia

http://www.w3.org/2001/XMLSchema#string

Ernesto Di Cesare

http://www.w3.org/2001/XMLSchema#string

Flora Vitale

http://www.w3.org/2001/XMLSchema#string

Francesco Marampon

http://www.w3.org/2001/XMLSchema#string

Giovanni Luca Gravina

http://www.w3.org/2001/XMLSchema#string

Giulia Rossi

http://www.w3.org/2001/XMLSchema#string

Judith A Fox

http://www.w3.org/2001/XMLSchema#string

P2860

DNA T OPOISOMERASES : Structure, Function, and Mechanism

Recent advances in understanding structure–function relationships in the type II topoisomerase mechanism

Impacts of Ionizing Radiation on the Different Compartments of the Tumor Microenvironment

Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II

Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.

Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo.

An off-target nucleostemin RNAi inhibits growth in human glioblastoma-derived cancer stem cells

Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.

Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth

P304

29865-29886

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.16168

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28415741

http://www.w3.org/2001/XMLSchema#string

P921

P932

5444710

http://www.w3.org/2001/XMLSchema#string